Eli Lilly and Company

LLY

767.76 (1.35%) 10.36

691.32(B)

Health Care

Pharmaceuticals

Eli Lilly and Company discovers develops and markets human pharmaceuticals worldwide. The company offers Basaglar Humalog Humalog Mix 75/25 Humalog U-100 Humalog U-200 Humalog Mix 50/50 insulin lispro insulin lispro protamine insulin lispro mix 75/25 Humulin Humulin 70/30 Humulin N Humulin R and Humulin U-500 for diabetes; Jardiance Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products including Alimta Cyramza Erbitux Jaypirca Retevmo Tyvyt and Verzenio. In addition the company offers Olumiant for rheumatoid arthritis atopic dermatitis severe alopecia areata and COVID-19; Taltz for plaque psoriasis psoriatic arthritis ankylosing spondylitis and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder diabetic peripheral neuropathic pain generalized anxiety disorder fibromyalgia and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC) a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states including diabetes obesity cardiovascular diseases neurodegeneration and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals Inc.; F. Hoffmann-La Roche Ltd and Genentech Inc.; Biologics Inc. AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co. Ltd as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis Indiana.

Holdings:

Cost basis:

Eli Lilly and Company (LLY) price target and intrinsic value estimate

LLY's fair price estimate is $766.0

This valuation is based on a fair P/E of 28.5 and EPS estimates of $26.90

The median analyst price target for LLY is $1000.0.

Analyst price targets range from $580.0 to $1250.0

Is LLY overvalued or undervalued?

LLY is currently trading at $767.76

LLY is overvalued by 0% using the pevaluation method.

LLY is undervalued by 23% compared to median analyst price targets.

Do you agree with this valuation?

Valuation

PEvaluation

Low $556.8

Median $766.0

High $957.4

Fair P/E

Margin of safety

Analyst valuation

Low $580.0

Median $1000.0

High $1250.0

Strong Buy6

Buy14

Hold6

Sell0

Strong Sell1

Discounted cash-flow

TTM FCFFCF est.Growth FCFTerminal FCF

Discount rate:

10%

Terminal rate:

Growth phase length:

Growth phase rate:

10%

Economic moat: Very wide

Overview

Market data

Market cap:$691.32(B)

Enterprise value:$718.56(B)

Total Equity:$14.32(B)

Shares outstanding:900.43(M)

Div. yield:0.66%

P/S:16.92

P/E:82.64

P/FCF:492.15

P/B:48.53

EPS:$9.3

FCF per share:$1.6

Dividend per share:$5.0

Income (TTM)

Revenue$40.86(B)

Gross profit$33.06(B)

EBITDA$16.57(B)

Net income$8.37(B)

Gross margin80.9%

Net margin20.5%

Balance sheet

Total assets$75.61(B)

Total liabilities$61.29(B)

Cash & Short-term inv.$3.52(B)

Long-term debt$29.12(B)

Debt issued$16.01(B)

Debt repaid$-5.56(B)

Cash flow (TTM)

FCF$1.40(B)

CapEx$-4.63(B)

Dividends paid$-4.53(B)

Stock issued$0

Stock repurchased$-446.10(M)

Stock-based comp.$623.90(M)

Future Growth

Revenue

CAGR: 18.4%

FY+1$45.64(B)

FY+2$58.58(B)

FY+3$70.43(B)

FY+4$79.74(B)

FY+5$89.56(B)

Net Income

CAGR: 33.0%

FY+1$11.90(B)

FY+2$20.53(B)

FY+3$26.69(B)

FY+4$31.47(B)

FY+5$37.25(B)

EPS

CAGR: 33.2%

FY+1$13.15

FY+2$22.62

FY+3$29.54

FY+4$35.03

FY+5$41.38

FCF per share

CAGR: 46.2%

FY+1$11.36

FY+2$22.94

FY+3$31.08

FY+4$43.61

FY+5$51.92

Similar Companies

Historical Financials

Showing limited histrical data. Access 10+ years of financials now! Upgrade

YearlyQuarterly

Income

RevenueNet IncomeCOGSGross ProfitTotal OpEx.R&DSG&AOperating IncomeInterest ExpenseInterest IncomePre-tax incomeIncome tax

Cash flow

FCFCFONet IncomeD&AStock-based Comp.CFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures

Balance sheet

Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity

Shares outstanding

Shares (Basic)Shares (Diluted)

Per share data

EPS (Basic)EPS (Diluted)FCF/ShareDividend/ShareBook value/Share

Ratios

P/EP/FCFP/BP/SEV/EarningsEV/FCFDebt/EquityPayout ratio

Margins

Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin

Returns

ROICROAROCEROE

Market Cap.